Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $20.3M | 7 | 99.8% |
| Consulting Fee | $35,078 | 18 | 0.2% |
| Travel and Lodging | $606.17 | 3 | 0.0% |
| Food and Beverage | $457.61 | 14 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | $20.3M | 36 | $0 (2024) |
| GENZYME CORPORATION | $7,134 | 5 | $0 (2022) |
| Genentech USA, Inc. | $61.09 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,607 | 3 | VERTEX PHARMACEUTICALS INCORPORATED ($1,607) |
| 2023 | $2,938 | 4 | Vertex Pharmaceuticals Incorporated ($2,938) |
| 2022 | $13,207 | 8 | GENZYME CORPORATION ($7,134) |
| 2021 | $18.8M | 6 | Vertex Pharmaceuticals Incorporated ($18.8M) |
| 2020 | $6,355 | 4 | VERTEX PHARMACEUTICALS INCORPORATED ($6,355) |
| 2019 | $1.0M | 6 | VERTEX PHARMACEUTICALS INCORPORATED ($1.0M) |
| 2018 | $503,198 | 11 | Vertex Pharmaceuticals Incorporated ($503,198) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $29.23 | General |
| 10/24/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $90.23 | General |
| 09/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,487.50 | General |
| 12/20/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 12/06/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 06/01/2023 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $7.64 | General |
| 03/08/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 08/24/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 06/08/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $3,612.50 | General |
| 05/20/2022 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $6,450.00 | General |
| 05/20/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $500.00 | General |
| 05/20/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $80.03 | General |
| 05/20/2022 | GENZYME CORPORATION | — | Food and Beverage | Cash or cash equivalent | $78.30 | General |
| 05/20/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $26.14 | General |
| 04/13/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 12/20/2021 | Vertex Pharmaceuticals Incorporated | — | Royalty or License | Cash or cash equivalent | $15,000,000.00 | General |
| 12/20/2021 | Vertex Pharmaceuticals Incorporated | — | Royalty or License | Cash or cash equivalent | $3,750,000.00 | General |
| 11/17/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 06/09/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| 06/02/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $2,762.50 | General |
| 03/17/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $615.00 | General |
| 12/18/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 10/14/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,435.00 | General |
| 08/19/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 05/20/2020 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 36 | 75 | $19,763 | $5,343 |
| 2020 | 2 | 43 | 95 | $25,418 | $6,718 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 64 | $14,912 | $4,032 | 27.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $4,851 | $1,311 | 27.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 30 | 82 | $19,516 | $5,157 | 26.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $5,902 | $1,560 | 26.4% |
About Dr. David Friedman, M.D
Dr. David Friedman, M.D is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194763482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Friedman, M.D has received a total of $20.3M in payments from pharmaceutical and medical device companies, with $1,607 received in 2024. These payments were reported across 42 transactions from 3 companies. The most common payment nature is "Royalty or License" ($20.3M).
As a Medicare-enrolled provider, Friedman has provided services to 79 Medicare beneficiaries, totaling 170 services with total Medicare billing of $12,060. Data is available for 2 years (2020–2021), covering 4 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 06/02/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1194763482
Products in Payments
- Xolair (Biological) $61.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Joseph Bonventre, Md Phd, MD PHD
Nephrology — Payments: $178,338